- Home
- IRD vs ARKR Comparison
IRD vs ARKR Comparison
Compare IRD & ARKR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IRD
- ARKR
- Stock Information
- Founded
- IRD 2018
- ARKR 1983
- Country
- IRD United States
- ARKR United States
- Employees
- IRD N/A
- ARKR N/A
- Industry
- IRD
- ARKR Restaurants
- Sector
- IRD
- ARKR Consumer Discretionary
- Exchange
- IRD NYSE
- ARKR Nasdaq
- Market Cap
- IRD 38.8M
- ARKR 31.4M
- IPO Year
- IRD N/A
- ARKR N/A
- Fundamental
- Price
- IRD $0.99
- ARKR $11.16
- Analyst Decision
- IRD Strong Buy
- ARKR
- Analyst Count
- IRD 2
- ARKR 0
- Target Price
- IRD $7.00
- ARKR N/A
- AVG Volume (30 Days)
- IRD 206.9K
- ARKR 15.0K
- Earning Date
- IRD 05-15-2025
- ARKR 05-20-2025
- Dividend Yield
- IRD N/A
- ARKR 1.68%
- EPS Growth
- IRD N/A
- ARKR N/A
- EPS
- IRD N/A
- ARKR N/A
- Revenue
- IRD $10,992,000.00
- ARKR $181,046,000.00
- Revenue This Year
- IRD $22.00
- ARKR N/A
- Revenue Next Year
- IRD $100.89
- ARKR N/A
- P/E Ratio
- IRD N/A
- ARKR N/A
- Revenue Growth
- IRD N/A
- ARKR N/A
- 52 Week Low
- IRD $0.65
- ARKR $8.25
- 52 Week High
- IRD $2.18
- ARKR $17.76
- Technical
- Relative Strength Index (RSI)
- IRD N/A
- ARKR 62.15
- Support Level
- IRD N/A
- ARKR $9.12
- Resistance Level
- IRD N/A
- ARKR $12.50
- Average True Range (ATR)
- IRD 0.00
- ARKR 0.74
- MACD
- IRD 0.00
- ARKR 0.38
- Stochastic Oscillator
- IRD 0.00
- ARKR 66.50
About IRD OPUS GENETICS INC
Opus Genetics Inc is a clinical-stage ophthalmic biopharmaceutical company developing therapies to treat patients with inherited retinal diseases (IRDs) and therapies to treat patients with other retinal and refractive disorders. The pipeline includes adeno-associated virus (AAV)-based gene therapies that address mutations in genes that cause different forms of bestrophinopathy, Leber congenital amaurosis (LCA), and retinitis pigmentosa. The pipeline also includes Phentolamine Ophthalmic Solution 0.75%, a non-selective alpha-1 and alpha-2 adrenergic antagonist to reduce pupil size, and APX3330, a novel small-molecule inhibitor of Ref-1 to slow the progression of non-proliferative diabetic retinopathy.
About ARKR Ark Restaurants Corp.
Ark Restaurants Corp owns and operates around 17 restaurants and bars, 16 fast food concepts, and catering operations in the USA. The Las Vegas operations include New York Hotel & Casino Resort, hotel room service operations, banquet facilities, employee dining room, food court concepts, and a restaurant within the Planet Hollywood Resort and Casino. It operates a restaurant and a bar in the Resorts Atlantic City Hotel and Casino and a restaurant in the Tropicana Hotel and Casino. The Florida operations include The Rustic Inn in Dania Beach, Shuckers in Jensen Beach, JB's on the Beach in Deerfield Beach, The Blue Moon Fish Company in Fort Lauderdale, and fast food facilities in Tampa and Hollywood. In Alabama, it operates Original Oyster Houses in Gulf Shores and Spanish Fort.